Alison Joly, Ph.D., has worked in the biotechnology sector for more than 20 years serving in multiple roles involved in oncology drug discovery, development and commercialization. Prior to joining CytomX in April 2016 as senior vice president, program and alliance management, Dr. Joly spent 14 years at Exelixis, most recently serving as vice president of program management for oncology. She oversaw multiple external partnerships relating to early and mid-stage development assets and played a critical role in the development, approval and launch of COMETRIQTM (cabozantinib) for locally advanced metastatic medullary thyroid carcinoma. Prior to Exelixis, Dr. Joly served as a scientist at Scios and CV Therapeutics. Dr. Joly holds a bachelor of science and a doctorate in biochemistry from The University of Liverpool, U.K., and completed her postdoctoral research at University of Florida and University of California, Los Angeles.